打字猴:1.70056841e+09
1700568410 8﹒Emsley R,Oosthuizen P﹒The new and evolving pharmacotherapy of schizophrenia﹒Psychiatric Clinics of North America,2003,26(1):141-163
1700568411
1700568412 9﹒Fitton A,Benfield P﹒Clozapine:an appraisal of its pharmacoeconomic benefits in the treatment ofschizo phrenia﹒Pharmacoeconomics,1993,4(2):131-156
1700568413
1700568414 10﹒Foster RH,Goa KL﹒Risperidone﹒A pharmacoeconomic review of its use in schizophrenia.Pharmacoeco nomics,1998,14(1):97-133
1700568415
1700568416 11﹒Foster RH,Goa KL﹒Olanzapine A pharmacoeconomic review of its use in schizophrenia.Pharmacoeco nomics,1999,15(6):611-640
1700568417
1700568418 12﹒Franz M,Lis S,Pluddemann K,et al﹒Conventional versus atypical neuroleptics:subjective quality of life in schizophrenic patients﹒British Journal of Psychiatry,1997,170:422-425
1700568419
1700568420 13﹒Hamann J,Leucht S,Kissling W﹒Arethe second‐generation antipsychoticscost‐effective?A critical re view on the background of different health systems﹒Pharmacopsychiatry,2003,36(1):18-26
1700568421
1700568422 14﹒Kane JM,(ed﹒)﹒Drug Maintenance Strategies in Schizophrenia﹒Washington,D﹒C﹒:American Psychiatric Press,1984
1700568423
1700568424 15﹒Kane JM,Leucht S,Carpenter D,Docherty JP﹒The expert consensus guideline series:Optimizing phar macologic treatment of psychotic disorders﹒Journal of Clinical Psychiatry,2003,64(suppl 12):1-100
1700568425
1700568426 16﹒Kinon BJ﹒The routing use of Atyptical Antipsychotic Agents:Maintenance Therapy﹒Journal of Clinical Psychiatry,1998,59(suppl 19)
1700568427
1700568428 17﹒Marder SR﹒Schizophrenia:Somatic treatment﹒In:Sadock BJ,Sadock VA eds﹒Kaplan and Sadock’s Com prehensive Textbook of Psychiatry﹒7th ed﹒Philadelphia:Lippincott Willians and Wilkins,2000,1199-1209
1700568429
1700568430 18﹒Marder SR,Wirshing DA﹒Maintenance treatment﹒In:Hirsch SR,Weinberger DR eds﹒Schizophrenia 2nd edition﹒Oxford:Blackwell Publishing,2003,474-488
1700568431
1700568432 19﹒Miyamoto S,Duncan GE,Goff DC,Lieberman JA﹒Therapeutics of Schizophrenia﹒In:Davis KL,Charney D,Coyle JT,Nemeroff C eds﹒Neuropsychopharmacology:The Fifth Generation of Progress.Philadelphia:Lippin cott Williams and Wilkins,2002,775-808
1700568433
1700568434 20﹒Revicki DA,Genduso LA,Hamilton SH,et al﹒Olanzapine versus haloperidol in the treatment of schizo phrenia and other psychotic disorders:quality of life and clinical outcomes of a randomized clinical trial﹒Quality of Life Research,1999,8(5):417-426
1700568435
1700568436 21﹒Robinson D,Woerner MG,Alvir JMJ,et al﹒Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder﹒Archives of General Psychiatry,1999,56:241-247
1700568437
1700568438 22﹒Schooler NR﹒Reducing dosage in maintenance treatment of schizophrenia﹒Review and prognosis﹒British Journal of Psychiatry 1993,163(suppl 22):58-65
1700568439
1700568440 23﹒Tollefson GD,Beasley CM Jr,Tamura RN,Tran PV,Potvin JH﹒Blind,controlled,long‐termstudy of the comparative incidence of treatment‐emergent tardive dyskinesia with olanzapine or haloperidol﹒American Journal of Psychiatry,1997,154(9):1246-1254
1700568441
1700568442 24﹒Weiden P,Aquila R,Standard J﹒Atypical antipsychotic drugs and long‐term outcome in schizophrenia﹒Journal of Clinical Psychiatry,1996,57(Suppl 11):53-60
1700568443
1700568444 25﹒Kane J,Leucht S,et al﹒The expert consensus guideline series optimizing pharmacologic treatment of psychotic disorders﹒Journal of Clinical Psychiatry,2003,64(suppl 12):39
1700568445
1700568446
1700568447
1700568448
1700568449 精神分裂症的康复操作手册 [:1700566502]
1700568450 精神分裂症的康复操作手册 第四章 精神障碍的家庭干预
1700568451
1700568452 精神分裂症的康复操作手册 [:1700566503]
1700568453 第一节 概 述
1700568454
1700568455 一、什么是精神障碍的家庭干预
1700568456
1700568457 新型抗精神病药用于临床以后,对精神分裂症的症状有确实的疗效,但是并没有改变精神分裂症的预后发展进程;例如,精神分裂症导致社会适应能力损害和参与市场就业竞争能力下降等,这种状况也并没有因为新型抗精神病药的引入而有所改变。有的患者在用药后,症状明显好转,但是仍残留有影响精神功能的残留症状,他们的社交技能也难以完全恢复,并且有相当大数量的病例,即使他们能按医嘱服药,也免不了复发。因此,有必要将心理和社会治疗引入整个治疗过程之中,并成为不可缺少的内容。心理社会治疗包括很多内容,其中有:家庭干预(family intervention)、社会技能训练(social skills training)和认知行为治疗(cognitive behavior therapy)等。患者经过药物治疗后绝大部分将继续生活在社区中,在社区中生活的患者又是离不开家庭的,因此家庭是患者最重要的直接社会环境(见第二章有关临床社会学的内容),家庭环境的特征极大地影响着疾病的预后。因此,对家庭干预的研究很多。
1700568458
1700568459 精神障碍的家庭干预简称家庭干预(family intervention),它是将药物治疗、家庭教育、危机干预等手段巧妙地结合在一起的一种治疗手段。
[ 上一页 ]  [ :1.70056841e+09 ]  [ 下一页 ]